Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2018 | An overview of 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias

Arnold Ganser • 4 May 2018
ESH AL 2018
Acute Myeloid Leukemia

Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany talks about his experience of the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, where he discusses the quality of the presentations being held at the event, the exciting conversations with other experts such as current controversies surrounding acute leukemia research, and the overall atmosphere of the conference.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Arnold Ganser

Finding the right targets for CAR T-cell therapy in AML
1:41
Finding the right targets for CAR T-cell therapy in AML
Arnold Ganser • 4 May 2018
Midostaurin: the first drug to receive approval for AML since 2000
2:28
Midostaurin: the first drug to receive approval for AML since 2000
Arnold Ganser • 4 May 2018
Overcoming the issues with clinical trial recruitment
1:37
Overcoming the issues with clinical trial recruitment
Arnold Ganser • 4 May 2018
The devastating effects of relapsed or refractory AML
3:00
The devastating effects of relapsed or refractory AML
Arnold Ganser • 4 May 2018

Related Videos

Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
8:41
Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
Roland Walter • 20 Sep 2026
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
8:33
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
Hima Atluri • 20 Sep 2026
How and when to use oral decitabine in AML
12:38
How and when to use oral decitabine in AML
Gail Roboz • 20 Sep 2026
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
22:07
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
Amir Fathi • 20 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals